HB334

Georgia HB334 establishes the Sickle Cell Disease Protection Act, requiring annual reviews of sickle cell disease treatments for Medicaid recipients.

Georgia HB334, the Sickle Cell Disease Protection Act, mandates the Department of Community Health to annually review medications and treatments for sickle cell disease among Medicaid recipients. The review aims to assess the adequacy of current treatments and identify potential additions. The department must solicit public input, particularly from those knowledgeable about sickle cell disease treatment. An annual report detailing the review findings and recommendations is to be submitted to the General Assembly by January 15 each year and published on the department's public website.